445 related articles for article (PubMed ID: 26088008)
1. Synthetic biology in cell-based cancer immunotherapy.
Chakravarti D; Wong WW
Trends Biotechnol; 2015 Aug; 33(8):449-61. PubMed ID: 26088008
[TBL] [Abstract][Full Text] [Related]
2. Synthetic biology approaches in cancer immunotherapy, genetic network engineering, and genome editing.
Chakravarti D; Cho JH; Weinberg BH; Wong NM; Wong WW
Integr Biol (Camb); 2016 Apr; 8(4):504-17. PubMed ID: 27068224
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
4. A synthetic biology approach to engineering circuits in immune cells.
Hoces D; Miguens Blanco J; Hernández-López RA
Immunol Rev; 2023 Nov; 320(1):120-137. PubMed ID: 37464881
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptors: driving immunology towards synthetic biology.
Sadelain M
Curr Opin Immunol; 2016 Aug; 41():68-76. PubMed ID: 27372731
[TBL] [Abstract][Full Text] [Related]
6. Engineered cell-based therapies: a vanguard of design-driven medicine.
Dudek RM; Chuang Y; Leonard JN
Adv Exp Med Biol; 2014; 844():369-91. PubMed ID: 25480651
[TBL] [Abstract][Full Text] [Related]
7. Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials.
Esensten JH; Bluestone JA; Lim WA
Annu Rev Pathol; 2017 Jan; 12():305-330. PubMed ID: 27959633
[TBL] [Abstract][Full Text] [Related]
8. Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy.
Zhu B; Yin H; Zhang D; Zhang M; Chao X; Scimeca L; Wu MR
Cell Mol Immunol; 2024 May; 21(5):436-447. PubMed ID: 38605087
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Biology: Immunotherapy by Design.
Brenner J; Cho JH; Wong NML; Wong WW
Annu Rev Biomed Eng; 2018 Jun; 20():95-118. PubMed ID: 29345976
[TBL] [Abstract][Full Text] [Related]
10. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
Houot R; Schultz LM; Marabelle A; Kohrt H
Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
[TBL] [Abstract][Full Text] [Related]
11. Adoptive T-cell therapy for cancer: The era of engineered T cells.
Bonini C; Mondino A
Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
[TBL] [Abstract][Full Text] [Related]
12. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
[TBL] [Abstract][Full Text] [Related]
13. Boolean logic in synthetic biology and biomaterials: Towards living materials in mammalian cell therapeutics.
Bressler EM; Adams S; Liu R; Colson YL; Wong WW; Grinstaff MW
Clin Transl Med; 2023 Jul; 13(7):e1244. PubMed ID: 37386762
[TBL] [Abstract][Full Text] [Related]
14. Engineering advanced cancer therapies with synthetic biology.
Wu MR; Jusiak B; Lu TK
Nat Rev Cancer; 2019 Apr; 19(4):187-195. PubMed ID: 30837696
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response.
Themeli M; Sadelain M
Trends Mol Med; 2016 Apr; 22(4):271-273. PubMed ID: 26971630
[TBL] [Abstract][Full Text] [Related]
16. From synthetic biology to human therapy: engineered mammalian cells.
Scheller L; Fussenegger M
Curr Opin Biotechnol; 2019 Aug; 58():108-116. PubMed ID: 30933864
[TBL] [Abstract][Full Text] [Related]
17. Theranostic cells: emerging clinical applications of synthetic biology.
McNerney MP; Doiron KE; Ng TL; Chang TZ; Silver PA
Nat Rev Genet; 2021 Nov; 22(11):730-746. PubMed ID: 34234299
[TBL] [Abstract][Full Text] [Related]
18. Synthetic biology, genetic circuits and machine learning: a new age of cancer therapy.
Prasad K; Cross RS; Jenkins MR
Mol Oncol; 2023 Jun; 17(6):946-949. PubMed ID: 37002698
[TBL] [Abstract][Full Text] [Related]
19. Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.
Wang C; Ye Y; Hu Q; Bellotti A; Gu Z
Adv Mater; 2017 Aug; 29(29):. PubMed ID: 28556553
[TBL] [Abstract][Full Text] [Related]
20. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
